October 26, 2016 6:36am
… Imagine if a company clicked a “selfie” as a self-portrait of its investor image; would it be embarrassing or flattering?
It’s still all about what “they” represent to investors …
I answer one question; in which company should investors put, keep and commit their money!
RegMed Investors’ (RMi) provides exclusive and original content; put your eyes on the page to figure out what’s really going on! If you are not a subscriber, you won’t know the morning’s indications and who is in the headlights.
I write in every line that investors need to avoid risks as if I were the first to be hurt if I am wrong!
BUY: AGTC and BTX
SELL: BSTG
Indexes and ETFs: The IBB (-0.19%) and IWM (-0.74%) are DOWN while the XLV and XBI are NOT indicating
Dow futures are DOWN -0.43% and NASDAQ futures are DOWN -0.54%
U.S. stock index futures pointed to a solidly lower open on Wednesday. One reason is Apple posted one of the biggest premarket losses after a disappointing outlook for the current quarter. A continued drop in oil prices also weighed, and investors waited for another round of results from big names.
European stocks were lower following lackluster trade on Wall Street and in Asia amid a slide in the oil price.
Asian markets were deflated by Australian shares, with shares of Ardent Leisure, operator of Dreamworld theme park, tumbling 14.89% to 2 Australian dollars a share ($1.54) after four people were killed due to an apparently malfunctioned ride on Tuesday. The ASX 200 fell 83.03 points, or 1.53%, to 5,359.79.
Data Docket: U.S. trade deficit numbers and Markit flash US services PMI are due out at 8.30 a.m. ET and 9.45 a.m. ET, respectively, while new home sales are expected at 10.00 a.m. ET. Mortgage Applications will come out at 7.00 a.m. ET.
The stem, cell, gene and regenerative therapy (SCG&RT) sector closed NEGATIVE on Tuesday, Monday and Friday, POSITIVE on Thursday and NEGATIVE last Wednesday.
The SCG&RT sector’s record after the last 5 days (of 43 covered companies):
· Tuesday closed NEGATIVE with 28 decliners, 9 advancers and 6 flats;
· Monday closed NEGATIVE with 27 decliners, 10 advancers and 6 flats;
· Friday closed NEGATIVE with 23 decliners, 17 advancers and 3 flats;
· Thursday closed POSITIVE with 16 decliners, 25 advancers and 2 flats;
· Wednesday closed NEGATIVE with 26 decliners, 14 advancers and 3 flat
Remembering Tuesday’s closing post, “The sector struggles with buoyancy as quarterly reporting season begins. Technicals and support are weak as resistance strengthens.”
- Reiterating, the stem, cell, gene and regenerative therapy (SCGT&RT) sector opened positive, slipped negative at the mid-day and closed negative. Even with a “crap” day in the sector, there will be an opportunity for upside follow through.”
Widespread oversold conditions, after Monday, Tuesday and last week multiply among sector “participants”!
Re the title, selfies are how an image is presented, some by posting pictures publicly or sharing them with others who do so … which may also have the opposite effect.
- Love ‘em or hate ‘em, selfies are harmless fun but, are they? Maybe not, selfies in this context … could say a lot about a company’s personality, and not in a good way.
- To investors, it could be a segway to transparency, governance and ways to communicate?
I further state that communicating with or to investors is better than … at them which most companies fail to understand.
You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades?
Watch list:
· The iShares Nasdaq Biotechnology (IBB) closed Tuesday down -0.46% and is DOWN -0.19% in Wednesday’s pre-market;
· The SPDR S&P Biotech ETF (XBI) closed Tuesday down -0.81% and is NOT indicating in Wednesday pre-market;
· The Health Care Select Sector SPDR ETF (XLV) closed down -0.29% Tuesday and is NOT indicating in Wednesday’s pre-market;
· The iShares Russell 2000 (IWM) closed down -0.75% on Tuesday and is DOWN -0.74% in Wednesday’s pre-market.
Companies in my headlights:
Applied Genetic Technologies (AGTC) closed DOWN -$0.10 to $8.10 following Monday’s $8.20 (-$0.05) after Friday’s $8.25 (-$0.75) following Thursday’s $9.00, Wednesday’s $8.70 and last Tuesday’s $8.70. What has changed, AGTC has a substantial cash position of $172.7 M, revenue, no debt, and a named partner – Biogen (BIIB), multiple trials as well as pre-clinical programs and on-going research in a hot universe. Book value per share is $9.87 and there is NO need for a capital markets offering; with a float of 9.88 M shares with 52.30% held by institutions and 18.05 M outstanding with 51.15% held by insiders are positives. I’d be buying for the upside - OVERSOLD – Maintaining BUY;
Biostage (BSTG) closed UP +$0.05 to $0.92 in a day’s range of $0.88 to $0.97. The day traders could target the upside with a trading solution and clean-up their “brass” – SELL;
BioTime (NYSEMKT: BTX) closed DOWN -$0.01 to $3.50 after Monday’s $3.51 (-$0.06). BTX is UNDERVALUED based on the week’s momentum - Friday’s $3.57, Thursday’s $3.58 and last Wednesday’s $3.49. It’s still the big casino – BUY;
Spark Therapeutics (ONCE) closed DOWN -$1.56 to $51.06 following Friday’s $52.42, Thursday’s $51.65, Wednesday’s $51.39 and last Tuesday’s $53.91.New has been slow while the vagaries of the market have been high – Maintaining BUY;
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Henry’s comments are for informational purposes only and are not a substitute for personalized advice. Consult your advisor about what is best for you.
